StockData

Opus Genetics vs uniQure

IRD and QURE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IRD and QURE compare

uniQure is the larger company, worth 4.5 times as much as Opus Genetics ($1.5B against $336M).

uniQure grew revenue faster over the last twelve months (30.2% versus −36.1% for Opus Genetics).

Opus Genetics keeps more of each dollar of sales as profit, with a net margin of −1092% compared with −1351% at uniQure.

Opus Genetics scores higher on the StockData Score (5 against 4 for uniQure), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIRDQURE
Size and price
Market cap$336M$1.5B
Share price$4.04$21.88
Change, 1 year118%−27.9%
Change, 5 years−7.1%−24.1%
Beta (5Y)0.103.07
Employees27221
StockData Score
Total score5 (better)4
Valuation score00
Growth score02 (better)
Performance score1 (better)0
Health score4 (better)2
Dividend score00
Valuation
P/S34.1× (better)81.3×
P/B–4.7×
FCF yield–−10.6%
Fair value–$6.38
Margin of safety–−243%
Growth
Revenue growth (TTM)−36.1%30.2% (better)
Revenue growth, 5Y average–−15.6%
Profitability
Gross margin–92.5%
Operating margin−513% (better)−1072%
Net margin−1092% (better)−1351%
FCF margin–−865%
Return on equity−4797%−158% (better)
Financial health
Debt / equity–0.15
Interest coverage−186.1×−3.4× (better)
Current ratio12.19 (better)10.01
Altman Z-score−2.64−0.44 (better)
Piotroski F-score44
Dividends and buybacks
Buyback yield−2.3%–
Shareholder yield−2.3%0.00% (better)
Ownership
Held by institutions72.8%96.0%
Held by insiders37.6%2.1%
Insider net buying, 12 months−$19.4M (better)−$20.2M
Short interest, % of float20.9%12.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.